Innovation Theater 4
Supported By: Sanofi and Regeneron

---

Program Description

Eosinophils can serve as a clinically valuable biomarker of type 2 inflammation in COPD, but are impacted by many factors. Join us for a case-based discussion on type 2 inflammation and how predictive biomarkers can help address exacerbations and lung function decline in patients with COPD. Experience an interactive session where you’ll hear about a treatment option that targets key sources of inflammation in COPD.

Speakers

Presenter: Geoffrey Chupp, MD
Yale University School of Medicine
Division of Pulmonary, Critical Care and Sleep Medicine
Professor of Internal Medicine
New Haven, Connecticut

Presenter: Xuanha (Mimi) White, DO
Integra Health PC
President and Pulmonary/Sleep Medicine Specialist
Temecula, California